RXRX Jan 2025 9.000 call
| Previous close | 2.2000 |
| Open | 2.0000 |
| Bid | 1.8000 |
| Ask | 2.0500 |
| Strike | 9.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.0000 - 2.1200 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.64k |
GuruFocus.comInsider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)
On May 28, 2024, Blake Borgeson, Director at Recursion Pharmaceuticals Inc (NASDAQ:RXRX), executed a sale of 11,447 shares of the company.
Insider MonkeyHedge Funds are Loading Up on This NVIDIA Corp (NVDA) Partner Stock
We recently published a list of 7 lesser-known, under-the-radar AI stocks hedge funds are piling into. Since RXRX is part of the list, the stock deserves a deeper look. Recursion Pharmaceuticals is an NVIDIA Corp (NASDAQ:NVDA) partner that will use the semiconductor giant’s chips and technology for drug discovery. The NVIDIA Corp (NASDAQ:NVDA) “effect” is now […]
GlobeNewswirePower of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in CRISPR-Cas9 gene knockouts and a debiasing (correcting) algorithm.SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highli
